Current trends in diagnostic tests of Invasive Candidiasis

Invasive Candidiasis – a deadly disease

Candida spp., commensal yeasts that colonize in our gut and on our skin could become lethal pathogens when they overgrow and disseminate into our bloodstream and deep-seated organs (lung, liver, spleen, kidneys, bone, or eye) and then cause invasive candidiasis (IC). Bloodstream infection (BSI), also called candidemia and internal organ infection are two common forms of IC which are the predominant fungal hospital-acquired infections.

Candidemia is one of the most common hospital-associated infections with extremely high mortality rates among patients up to 75% worldwide

Additionally, the cost burden of the disease was substantial high. Invasive candidiasis was estimated as one of the highest healthcare costs of fungal diseases in the United States ($64,723–$153,090 per hospitalization).

Unfortunately, there estimated 3-5 cases with candidemia for every 100,000 persons in the general population, and even higher in hospital or ICU admissions.

Why is timely diagnosis important?

Long-term ICU stay, central venous catheter, parenteral nutrition, immunosuppression, broad spectrum antimicrobial treatment, recent major surgery, dialysis, diabetes are most common risk factors associated with IC24. People developing IC usually have unknow fever, chill and do not response successfully to most antibacterial drugs. These unspecific and unclear clinical signs and symptoms make diagnosis be challenging. Thus, healthcare provider must rely on risk factors and symptoms and pathogen tests to determine IC.

Many studies showed that delayed diagnosis or misidentifications of Candida spp. led to delaying of initial treatment or inadequate treatment which were associated with the increase of death cases. It emphasizes that the rapid diagnostic methods are crucial to the improvement of outcomes of patients with Candida bloodstream infections.

The aetiological shift is also a reason for demanding of a diagnostic test with high specificity to detect the resistance and choose the optimal treatment regimens. Among various Candida pathogens, the five major causes of IC are Candida albicans, Candida glabrata, Candida tropicalis, Candida parapsilosis and Candida krusei .Whereas C. albicans still remains the first rank in prevalence, there has been an epidemiological shift in non-albicans Candida species in the last decades. Different Candida spp. differ substantially in virulence and drug susceptibility. Although C. albicans is susceptible to most of antifungal drugs, other Candida species pose considerable multidrug resistance. Moreover, a previously rare Candida pathogen, Candida auris, showed high resistance to fluconazole, amphotericin B and caspofungin, has globally spreading in more than 30 countries on six continents.

Current trends in diagnostic tests

There are some approaches applied worldwide to detect Candida spp., each one has its own advantages and drawbacks(Table 1).

 

Specimen types and invasive candidiasis diagnostic tests

Table 1. Specimen types and invasive candidiasis diagnostic tests

According to US CDC, fungal culture from normally sterile sites such as blood, peritoneal fluid, and pleural fluid is widely used in clinicals as the gold standard test. However, the sensitivity of this method is only approximately 50% and the time to positivity ranges from 1 to 7 days. This is not the ideal candidate for timely diagnosis.

In recent years, three techniques approved by FDA may be helpful for IC diagnosis: matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF), the β-D glucan (Fungitell, Associates of Cape Cod, Inc, East Falmouth, MA) assay, and the T2Candida assay (T2 Biosystems, Lexington, MA).

MALDI-TOF uses mass spectroscopy to identify species in pure isolates. Its turnaround time for species identification is 10 – 15 minutes once the pure isolates are provided. It can determine non-albicans Candida spp. but still need culture step.

β-D glucan assay is a pan-fungal invasion test which cannot distinguish between Candida spp. and other fungi. Although the sensitivity of this assay ranged from 76.7% to 100%, the specificity varied from 40% to 91.8%. The limitations of this approach are non-specificity, high cost and difficulty in performance.

T2 Candida assay is magnetic resonance assay based on PCR technique which can directly detect five common candidemia pathogens (C. albicansC. tropicalisC. parapsilosisC. krusei, and C. glabrata) in whole blood samples in as soon as 3 to 4 hours. However, the test results are categorized into three groups (not singe species determination): C. albicans or C. tropicalisC. glabrataC. kruseiS. cerevisiae or C. bracarensis; or C. parapsilosisC. metapsilosis or C. orthopsilosis.

Other PCR-based assays are effective diagnostic tests with high sensitivity, single species identification and timeliness, compared with culture methods . Until now, the most thoroughly validated PCR-based system is SeptiFast (Roche, Basel, Switzerland). This multiplex real-time PCR test has been reported in some studies in Europe to detect 19 bacteria and 6 fungi (C. albicans, C. glabrata, C. parapsilosis, C. tropicalis, C. krusei, and Aspergillus fumigatus) with sensitivity up to 94% . However, these assays still not widely validated in large-scale studies and cannot identify many Candida spp.

Nanopore sequencing is a promising method which can detect the missed or not detectable pathogens within 6 hours (including pre-sequencing preparation). It was also an expeditious tool to analyze the epidemiology of the C. auris outbreak.

With continuously improvement, Nanopore method will be the game changer in the effort of increasing the survival rates of patients with IC and minimizing economic burden as well.

Micronbrane Medical provides easy and rapid solution with two products: Devin® and PaRTI-Seq® (Pathogen Real-Time Identification by Sequencing). Devin® membrane produces pathogen-enriched samples ready for downstream diagnostic applications. PaRTI-Seq® technology combines the latest third-generation sequencing (Nanopore Sequencing) and proprietary analytical methods, to provide test results within 22 hours.

Disclaimer:

Micronbrane Medical is a Biotech Company focusing on pathogen detection. All facts presented here are based on the referenced peer-reviewed international scientific journals and are the culmination of years-long global scientific research.